Categories Earnings, Technology
Coupa Software’s top and bottom line results for Q1 exceeds estimates
Coupa Software (Nasdaq: COUP) reported an adjusted loss of 3 cents per share on revenue of $81 million for the first quarter of fiscal 2020. Analysts had expected Coupa to post a loss of 4 cents per share on revenue of $73.8 million. COUP stock, which closed down 6.16% at $102.48, was up about 5% in the extended hours of trading.
The revenue increase of 44% compared to the year-ago period was driven by subscription revenue growth of 46%. GAAP net loss was $20.5 million or $0.34 per share compared to a loss of $15.5 million or $0.28 per share in the same period last year. For the first quarter of fiscal 2020, revenue and adjusted EPS came in line with the company’s targets.
For the second quarter of 2020, the San Mateo, California-based firm expects the non-GAAP loss to be between $0.10 and $0.12 per share and revenue is expected to be between $84.5 million and $85.5 million. Subscription revenues are expected to be between $77 million and $78 million. Professional services and other revenues are expected to be approximately $7.5 million.
Coupa lifted its outlook for the fiscal year 2020. The company now projects adjusted earnings to be in the range of $0.07 to $0.10 per share versus the prior estimate of $0.04 to $0.10. The prior revenue gudiance range of $325 million to $327 million is now upped to a range of $342 million and $344 million.
“In the first quarter, we delivered strong financial results, including record quarterly total revenues, subscription revenues, and calculated billings, as we continued to execute on our business plan and further solidify our position as the clear leader in Business Spend Management,” said CEO Rob Bernshtey.
Coupa Software stock, which reached a new 52-week high ($116.13) on May 22, had returned 61% since the beginning of 2019 and 87% in the trailing 12 months.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on